Mode
Text Size
Log in / Sign up
Phase 2 N=23 Treatment

Study of Nicotinamide in Early Onset Preeclampsia

Pre-Eclampsia · Pregnancy Related

Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Sep 2022
Primary outcome: Primary: Change in Mean Arterial Blood Pressure (MAP) — 0; 2; 4 mmHg

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
nicotinamide (Drug)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
University of North Carolina, Chapel Hill
Primary completion
Aug 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Mean Arterial Blood Pressure (MAP)
0; 2; 4
SECONDARY
Number of Participants With Alanine Aminotransferase (ALT) =/> 3x Upper Limit of Normal (ULN)
SECONDARY
Number of Participants With Aspartate Aminotransferase (AST) =/> 3x Upper Limit of Normal (ULN)
SECONDARY
Number of Participants With Maternal Side Effects
0; 0; 0
SECONDARY
Percentage of Women Maternal Abdominal Tenderness
0; 0; 0
SECONDARY
Percentage of Women With Headache Unrelieved by Oral Analgesics
33; 0; 0
SECONDARY
Percentage of Women With Hematocrit Decrease of More Than 3%
44
SECONDARY
Percentage of Women With Less Than 500 cc Urine Output in 24 Hours
SECONDARY
Percentage of Fetuses With Category III Non Stress Test Results
SECONDARY
Percentage of Fetuses With Biophysical Profile < 6
SECONDARY
Mean Peak Nicotinamide Level
12701.7; 13279.7; 16314.1
SECONDARY
Mean Trough Concentration Nicotinamide Administration
479.2; 1490.7; 1991.2

Summary

Phase II Study of 2.5 gm of nicotinamide, given daily in 3 divided doses, to measure effect on maternal blood pressure in women with early onset preeclampsia and to determine peak and trough levels of nicotinamide. We will compare peak and trough levels in healthy non-pregnant and healthy pregnant participants.

Eligibility Criteria

Diagnosis and Inclusion Criteria

  • Maternal age 18-55 years
  • Singleton pregnancy with no known fetal anomalies
  • Early-onset preeclampsia OR early-onset severe gestational hypertension defined as:
  • Early-onset: between 24 weeks 0 days and -33 weeks 3 days, based on menstrual dating confirmed by first or second trimester ultrasound OR second trimester ultrasound if menstrual dating unavailable;
  • Preeclampsia:
  • New onset hypertension and proteinuria, with systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg on two occasions 6 hours apart and > 300 mg proteinuria on 24 hour urine collection OR urine P/C ratio >0.3;
  • New onset hypertension and NO proteinuria, with systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg on two occasions 6 hours apart and one or more of the following: serum creatinine >1.1 mg/dL or doubling from baseline ,or central nervous system symptoms or visual changes
  • Severe preeclampsia defined as new onset systolic BP > 160 mm Hg and/or diastolic BP > 105 with proteinuria as above or or without proteinuria and one or more of the following criteria listed above
  • Candidate for expectant management for at least 48 hours
  • Deemed clinically stable by primary clinician and candidate for expectant management (delayed delivery) for at least 48 hours;
  • Maternal liver function tests 100,000 mm³
  • Planned expectant management
  • Pre-existing medical diseases such as hypertension, diabetes, endocrine disorders, gastrointestinal diseases, are well controlled
  • Fetal well-being established by estimated fetal weight > 5th %tile; normal amniotic fluid volume (MVP > 2 cm); normal Umbilical Artery (UA) Dopplers; or reactive Non Stress Test (NST) or Biophysical Profile (BPP) > 6
  • Delivery not anticipated within 48 hours of enrollment

Exclusion Criteria

  • Pre-existing renal disease (creatinine > 1.5 mg/dL)
  • Any pre-existing medical condition that would increase risk for liver toxicity (e.g. hepatitis B or C; HIV; Isoniazid (INH) use)
  • Eclampsia; cerebral edema on CT/MRI; headache unrelieved by analgesics
  • Evidence of liver dysfunction (LFTs > 2x ULN)
  • Thrombocytopenia (platelets < 100,000 mm³)
  • Pulmonary edema
  • HELLP syndrome
  • Evidence of fetal compromise: Estimated Fetal Weight (EFW) < 5th percentile; or BPP < 6; or absent or reverse diastolic UA blood flow; or oligohydramnios (MVP < 2 cm)
  • Placental abruption defined as unexplained vaginal bleeding
  • Preterm labor defined as regular contractions and cervical change
  • Any condition deemed by the investigator to be a risk to mother or fetus in completion of the study
  • Any condition deemed by the investigator to require delivery within 48 hours
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03419364). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search